Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen presented updated long-term durability data for PAPZIMEOS at the ASCO Annual Meeting, showing that 83% of complete responders maintained their response for at least 36 months without additional treatment. Five patients have demonstrated ongoing complete responses beyond four years, with no new adverse safety events observed during the extended follow-up period.
Key figures
- Drug Name
- PAPZIMEOS (zopapogene imadenovec-drba)
- Ongoing response pct
- 83%
- Ongoing response count
- 15
- Patients beyond 4 years
- 5
- Response duration months
- 36 to 51
- Complete responders total
- 18
- Us rrp patient population
- 27000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.